Biomarin Pharmaceutical Inc
(NAS:BMRN)
$
67.725
0.655 (0.98%)
Market Cap: 12.91 Bil
Enterprise Value: 12.43 Bil
PE Ratio: 40.55
PB Ratio: 2.38
GF Score: 69/100 Biomarin Pharmaceutical Inc at Leerink Partners Global Healthcare Conference Transcript
Feb 27, 2019 / 02:00PM GMT
Release Date Price:
$93.77
(+1.74%)
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Analyst
Good morning. Welcome to the BioMarin fireside chat. It's my pleasure to get us started. I'm Joe Schwartz from biotech research team at SVB Leerink, and I'm pleased to be joined by BioMarin's Senior Vice President and CMO, Geoff Nichol. And a very exciting time for BioMarin on a number of fronts. Geoff's going to start us off with some slides, and then we'll go into Q&A. If you have anything you'd like to ask, just raise your hand and we'll address that. Thank you, Geoff.
Geoffrey M. Nichol
BioMarin Pharmaceutical Inc. - Senior VP, Chief Medical Officer & Head of Global Clinical Development
Okay. Thank you very much for the opportunity to present on behalf of BioMarin.
Why is it not advancing? Not going, I'm afraid.
Joseph Patrick Schwartz
SVB Leerink LLC, Research Division - MD of Rare Diseases & Senior Analyst
Can we get the slides to advance? There we go.
Let's try again. Thank
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot